Connected Blood Glucose Monitoring from Evidence to Clinical Practice

Dr Banshi Saboo, Ahmedabad

• Blood glucose monitoring is a cornerstone for the management of diabetes and helps health care providers:

• To assess glycemic control
• Adjust therapy accordingly
• Help patients modify their lifestyle accordingly.

• Structured monitoring, pattern analysis and specific actions based on pattern providers better control of both hyperglycemia and hypoglycemia.
• Patients and physicians connecting blood glucose monitors ease the burden such as logbook main­tenance, data sharing, evaluating blood glucose readings and remote monitoring.

PIONEERing the New Revolution in the Management of T2DM with Oral Semaglutide

Dr Anil Bhansali, Chandigarh

• Oral semaglutide demonstrated significantly greater glycosylated hemoglobin (HbA1c) and weight reductions versus sitagliptin, empa­gliflozin and
• Oral semaglutide is superior compared to empa­gliflozin and sitagliptin in controlling HbA1c, while noninferior to liraglutide.
• Oral semaglutide has superior weight reduction properties compared to sitagliptin, linagliptin and empagliflozin.
• Cardiovascular safety: Confirmed for oral sema­glutide in PIONEER 6, showing a 21% nonsignificant reduction in major adverse cardiovascular events in favor of oral semaglutide compared with placebo.
• Overall safety: Oral semaglutide was well-tolerated with a safety profile consistent with the glucagon-like peptide-1 receptor agonist (GLP-1RA) class. The most common adverse event was mild to moderate nausea.
• Efficacy was established when given early in therapy, late in therapy and regardless of renal or hepatic impairment.

2022 Update in Diabetes

Dr AK Das, Puducherry

• Remarkable advances were observed in recent years in the management of patients with type 2 diabetes mellitus (T2DM) or type 1 diabetes mellitus (T1DM).
• Regarding T2DM, changes in treatment paradigms were observed, moving from a glucocentric approach to a multi-risk strategy and, finally, in people at high-risk, to specific cardiorenal protection using new antidiabetic agents.
• Regarding T1DM, progress combined new insulin analogs with better pharmacokinetics, continuous and flash glucose monitoring, and improved insulin delivery systems with smart insulin pens and insulin pumps connected to a glucose monitoring device, allowing better glucose control with less hypoglycemia.
• Because of an increasing variety of therapeutic approaches, an individualized patient-centered strategy is recommended, ideally with the collabo­ration of a multidisciplinary team.
• Artificial intelligence, digitization and telemedicine will play an increasing role in the management of T1DM and T2DM, in a near future.

Gliptin, Gliflozin, Synergy

Dr Vinod Mittal, New Delhi

• Robust/rapid HbA1c reduction – no added hypoglycemia.
• Weight loss – fat.
• Decrease in SBP…Uric acid.
• Cardiorenal protection.
• Less GTI.
• Cost, convenience, compliance.